1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BridgeBio May See Quicker Market Entry For Muscular Dystrophy Drug

 
• By Joseph Haas

BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope
BridgeBio hopes to earn accelerated approval for its drug for a subset of MD patients

On the heels of positive Phase III data for its cardiomyopathy drug, hub-and-spoke company BridgeBio Pharma, Inc. has another bit of good news with an agreement with the US Food and Drug Administration on potential accelerated approval for its oral therapy for a subset of limb-girdle muscular dystrophy. The company announced on 31 July a plan to use interim data from its Phase III trial measuring levels of the protein alpha-dystroglycan (αDG) that might show that BB-418 is working on the disease’s underlying cause and read out by late 2024 or early 2025.

Being developed by BridgeBio portfolio company ML Bio Solutions, BB-418 has shown improved and stable levels of αDG over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Sanofi Cements RSV Dominance As Merck & Co Rival Awaits FDA D-Day

 
• By Kevin Grogan

The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.

Pipeline Watch: ASCO Dominates Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

More from R&D

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.